The role of glucuronidation in drug resistance

Pharmacology and Therapeutics

Volumn 159, Issue , 2016, Pages 35-55

  Mazerska, Zofia ^a   Mróz, Anna ^a   Pawłowska, Monika ^a   Augustin, Ewa ^a  

^a GDANSK UNIVERSITY OF TECHNOLOGY   (Poland)

Author keywords

ABC transporters; Antitumor drug resistance; Glucuronidation; UGT dependent resistance; UGT modulated pharmacokinetics

Indexed keywords

ABC TRANSPORTER; ACRIDONE DERIVATIVE; ANTICONVULSIVE AGENT; ANTIHYPERTENSIVE AGENT; ANTIVIRUS AGENT; BELINOSTAT; BISPHOSPHONIC ACID DERIVATIVE; BREAST CANCER RESISTANCE PROTEIN; CALCITONIN; CALCIUM; DNA TOPOISOMERASE INHIBITOR; EMODIN; EPIRUBICIN; ETOPOSIDE; GLUCURONOSYLTRANSFERASE; HYPOCHOLESTEROLEMIC AGENT; IMMUNOSUPPRESSIVE AGENT; IRINOTECAN; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; PARATHYROID HORMONE; PREGNANE X RECEPTOR; PROTEIN P53; RALOXIFENE; SODIUM FLUORIDE; TAMOXIFEN; TRANSCRIPTION FACTOR GLI1; VITAMIN D;

ANTICONVULSANT THERAPY; BLADDER TUMOR; BLOOD BRAIN BARRIER; BRAIN TISSUE; BREAST CANCER; CANCER RESISTANCE; CANCER THERAPY; CANCER TISSUE; COLON CANCER; COLON TUMOR; DEPRESSION; DRUG DETOXIFICATION; DRUG ELIMINATION; DRUG EXCRETION; DRUG GLUCURONIDATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESISTANCE; ENZYME ACTIVITY; ENZYME METABOLISM; EPILEPSY; GLUCURONIDATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERTENSION; INTESTINE TUMOR; KIDNEY TUMOR; LIGAND BINDING; LIVER TUMOR; LUNG CANCER; NONHUMAN; OSTEOPOROSIS; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SCHIZOPHRENIA; STOMACH TUMOR; HIV INFECTIONS; MENTAL DISORDERS; METABOLISM; NEOPLASMS; PHYSIOLOGY;

ANTICHOLESTEREMIC AGENTS; ANTIHYPERTENSIVE AGENTS; DRUG RESISTANCE; EPILEPSY; GLUCURONOSYLTRANSFERASE; HIV INFECTIONS; HUMANS; HYPERTENSION; IMMUNOSUPPRESSIVE AGENTS; MENTAL DISORDERS; NEOPLASMS; OSTEOPOROSIS;

EID: 84959488906     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2016.01.009     Document Type: Review

References (251)

1. K. Akaba, T. Kimura, A. Sasaki, S. Tanabe, T. Ikegami, M. Hashimoto, and et al. Neonatal hyperbilirubinemia and mutation of the bilirubin uridine diphosphate-glucuronosyltransferase gene: a common missense mutation among Japanese, Koreans and Chinese Biochem Mol Biol Int 46 1998 21 26
2. N. Albin, L. Massaad, C. Toussaint, M.C. Mathieu, J. Morizet, O. Parise, and et al. Main drug-metabolizing enzyme systems in human breast tumors and peritumoral tissues Cancer Res 53 1993 3541 3546
3. K. Araki, K. Fujita, Y. Ando, F. Nagashima, W. Yamamoto, H. Endo, and et al. Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer Cancer Sci 97 2006 1255 1259
4. E. Aronica, J.A. Gorter, M. Ramkema, S. Redeker, F. Ozbas-Gerçeker, E.A. van Vliet, and et al. Expression and cellular distribution of multidrug resistance-related proteins in the hippocampus of patients with mesial temporal lobe epilepsy Epilepsia 45 2004 441 451
5. E. Aronica, S.M. Sisodiya, and J.A. Gorter Cerebral expression of drug transporters in epilepsy Adv Drug Deliv Rev 64 2012 919 929
6. R. Atsumi, W. Suzuki, and H. Hakusui Identification of the metabolites of irinotecan, a new derivative of camptothecin, in rat bile and its biliary excretion Xenobiotica 21 1991 1159 1169
7. J.W. Bae, C.I. Choi, J.H. Lee, C.G. Jang, M.W. Chung, and S.Y. Lee Effects of UDP-glucuronosyltransferase polymorphisms on the pharmacokinetics of ezetimibe in healthy subjects Eur J Clin Pharmacol 67 2011 39 45
8. A. Basseville, L. Preisser, S. de Carné Trécesson, M. Boisdron-Celle, E. Gamelin, O. Coqueret, and et al. Irinotecan induces steroid and xenobiotic receptor (SXR) signaling to detoxification pathway in colon cancer cells Mol Cancer 10 2011 80
9. B. Bauer, A.M. Hartz, G. Fricker, and D.S. Miller Modulation of p-glycoprotein transport function at the blood-brain barrier Exp Biol Med (Maywood) 230 2005 118 127
10. K.W. Bock Functions and transcriptional regulation of adult human hepatic UDP-glucuronosyl-transferases (UGTs): mechanisms responsible for interindividual variation of UGT levels Biochem Pharmacol 80 2010 771 777
11. K.W. Bock Human UDP-glucuronosyltransferases: feedback loops between substrates and ligands of their transcription factors Biochem Pharmacol 84 2012 1000 1006
12. K.W. Bock Homeostatic control of xeno- and endobiotics in the drug metabolizing enzyme system Biochem Pharmacol 90 2014 1 6
13. K.W. Bock, T. Eckle, M. Ouzzine, and S. Fournel-Gigleux Coordinate induction by antioxidants of UDP-glucuronosyltransferase UGT1A6 and the apical conjugate export pump MRP2 (multidrug resistance protein 2) in caco-2 cells Biochem Pharmacol 59 2000 467 470
14. J. Borlak, A. Gasparic, M. Locher, H. Schupke, and R. Hermann N-glucuronidation of the antiepileptic drug retigabine: results from studies with human volunteers, heterologously expressed human UGTs, human liver, kidney, and liver microsomal membranes of Crigler-Najjar type II Metabolism 55 2006 711 721
15. P. Borst, R. Evers, M. Kool, and J. Wijnholds A family of drug transporters, the MRPs J Natl Cancer Inst 92 2000 1295 1302
16. O. Bouché, J.L. Raoul, F. Bonnetain, M. Giovannini, P.L. Etienne, G. Lledo, and et al. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study-FFCD 9803 J Clin Oncol 22 2004 4319 4328
17. N. Bozina, M.R. Kuzman, V. Medved, N. Jovanovic, J. Sertic, and L. Hotujac Associations between MDR1 gene polymorphisms and schizophrenia and therapeutic response to olanzapine in female schizophrenic patients J Psychiatr Res 42 2008 89 97
18. B. Breitenstein, S. Scheuer, H. Pfister, M. Uhr, S. Lucae, F. Holsboer, and et al. The clinical application of ABCB1 genotyping in antidepressant treatment: a pilot study CNS Spectr 19 2014 165 175
19. R.W. Brockman Mechanisms of resistance to anticancer agents Adv Cancer Res 7 1963 129 234
20. R. Cacabelos, P. Cacabelos, and G. Aliev Genomics of schizophrenia and pharmacogenomics of antipsychotic drugs O J Psych 3 2013 46 139
21. L.E. Carlini, N.J. Meropol, J. Bever, M.L. Andria, T. Hill, P. Gold, and et al. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal patients treated with capecitabine/irinotecan Clin Cancer Res 11 2005 1226 1236
22. L.A. Carver, J.J. LaPres, S. Jain, E.E. Dunham, and C.A. Bradfield Characterization of the Ah receptor-associated protein, ARA9 J Biol Chem 273 1998 33580 33587
23. V. Cattori, B. Hagenbuch, N. Hagenbuch, B. Stiege, R. Ha, K.E. Winterhalter, and et al. Identification of organic anion transporting polypeptide 4 (Oatp4) as a major full-length isoform of the liver-specific transporter-1 (rlst-1) in rat liver FEBS Lett 474 2000 242 245
24. B. Cengiz, O. Yumrutas, E. Bozgeyik, E. Borazan, Y.Z. Igci, I. Bozgeyik, and et al. Differential expression of the UGT1A family of genes in stomach cancer tissues Tumour Biol 36 2015 5831 5837
25. B. Chandler, L. Almond, J. Ford, A. Owen, P. Hoggard, S. Khoo, and et al. The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on p-glycoprotein expression in peripheral blood mononuclear cells in vitro J Acquir Immune Defic Syndr 33 2003 551 556
26. G. Chang Multidrug resistance ABC transporters FEBS Lett 555 2003 102 105
27. Y. Chang, L.Y. Yang, M.C. Zhang, and S.Y. Liu Correlation of the UGT1A4 gene polymorphism with serum concentration and therapeutic efficacy of lamotrigine in Han Chinese of Northern China Eur J Clin Pharmacol 70 2014 941 946
28. N. Chau, D.J. Elliot, B.C. Lewis, K. Burns, M.R. Johnston, P.I. Mackenzie, and et al. Morphine glucuronidation and glucosidation represent complementary metabolic pathways that are both catalyzed by UDP-glucuronosyltransferase 2B7: kinetic, inhibition, and molecular modeling studies J Pharmacol Exp Ther 349 2014 126 137
29. J. Chen, G. Lu, J. Lin, A.L. Davidson, and F.A. Quiocho A tweezers-like motion of ATP binding cassette dimer in an ABC transport cycle Mol Cell 12 2003 651 661
30. S. Chen, P. St Jean, J. Borland, I. Song, A.J. Yeo, S. Piscitelli, and et al. Evaluation of the effect of UGT1A1 polymorphisms on dolutegravir pharmacokinetics Pharmacogenomics 15 2014 9 16
31. S. Chen, M.F. Yueh, C. Bigo, O. Barbier, K. Wang, and M. Karin Intestinal glucuronidation protects against chemotherapy-induced toxicity by irinotecan (CPT-11) Proc Natl Acad Sci U S A 110 2013 19143 19148
32. S.Y. Cho, S.C. Cosenza, V. Pallela, G. Panda, M.V. Ramana Reddy, E. Premkumar Reddy, and et al. Determination of the glucuronide metabolite of ON 013100, a benzylstyrylsulfone antineoplastic drug, in colon cancer cells using LC/MS/MS J Pharm Biomed Anal 75 2013 138 144
33. S.K. Cho, E.S. Oh, K. Park, M.S. Park, and J.Y. Chung The UGT1A3∗2 polymorphism affects atorvastatin lactonization and lipid-lowering effect in healthy volunteers Pharmacogenet Genomics 22 2012 598 605
34. C.H. Choi ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal Cancer Cell Int. 5 2005 1 13
35. W.M. Chołody, S. Martelli, and J. Konopa 8-Substituted 5-[(aminoalkyl)amino]-6H-v-triazolo[4,5,1-de]acridin-6-ones as potential antineoplastic agents. Synthesis and biological activity J Med Chem 33 1990 2852 2856
36. W.M. Chołody, S. Martelli, and J. Konopa Chromophore modified antineoplastic imidazoacridiones. Synthesis and activity against murine leukemias J Med Chem 35 1992 378 382
37. X.Y. Chu, Y. Kato, K. Niinuma, K.I. Sudo, H. Hakusui, and Y. Sugiyama Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats J Pharmacol Exp Ther 281 1997 304 314
38. X.Y. Chu, H. Suzuki, K. Ueda, Y. Kato, S.I. Akiyama, and Y. Sugiyama Active efflux of CPT-11 and its metabolites in human KB-derived cell lines J Pharmacol Exp Ther 288 1999 735 741
39. S. Clive, M.M. Woo, M. Stewart, T. Nydam, S. Hirawat, and M. Kagan Elucidation of the metabolic and elimination pathways of panobinostat (LBH589) using [14C]-panobinostat J Clin Oncol 27 2009 15 s
40. B.L. Coffman, C.D. King, G.R. Rios, and T.R. Tephly The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268) Drug Metab Dispos 26 1998 73 77
41. M.L. Cottrell, T. Hadzic, and A.D. Kashuba Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir Clin Pharmacokinet 52 2013 981 994
42. M.H. Court, X. Zhang, X. Ding, K.K. Yee, L.M. Hesse, and M. Finel Quantitative distribution of mRNAs encoding the 19 human UDP-glucuronosyltransferase enzymes in 26 adult and 3 fetal tissues Xenobiotica 42 2012 266 277
43. R.L. Cuff, L.T. Wade, B. Rychlik, G.A. Jedlitschky, and B. Burchell Characterisation of glucuronidation and transport in V79 cells co-expressing UGT1A1 and MRP1 Toxicol Lett 120 2001 43 49
44. Y. Cui, J. König, I. Leier, U. Buchholz, and D. Keppler Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6 J Biol Chem 276 2001 9626 9630
45. J. Cummings, G. Boyd, B.T. Ethell, J.S. Macpherson, B. Burchell, J.F. Smyth, and et al. Enhanced clearance of topoisomerase I inhibitors from human colon cancer cells by glucuronidation Biochem Pharmacol 63 2002 607 613
46. J. Cummings, B.T. Ethell, L. Jardine, G. Boyd, J.S. Macpherson, B. Burchell, and et al. Glucuronidation as a mechanism of intrinsic drug resistance in human colon cancer: reversal of resistance by food additives Cancer Res 63 2003 8443 8450
47. J. Cummings, B.T. Ethell, L. Jardine, and B. Burchell Glucuronidation of SN-38 and NU/ICRF 505 in human colon cancer and adjacent normal colon Anticancer Res 26 2006 2189 2196
48. J. Cummings, I. Meikle, J.S. Macpherson, and J.F. Smyth Accumulation of anthracenyl-amino acid topoisomerase I and II inhibitors in drug-sensitive and drug-resistant human ovarian cancer cell lines determined by high-performance liquid chromatography Cancer Chemother Pharmacol 37 1995 103 109
49. J. Cummings, N. Zelcer, J.D. Allen, D. Yao, G. Boyd, M. Maliepaard, and et al. Glucuronidation as a mechanism of intrinsic drug resistance in colon cancer cells: contribution of drug transport proteins Biochem Pharmacol 67 2004 31 39
50. D. Cunningham, J. Maroun, U. Vanhoefer, and E. Van Cutsem Optimizing the use of irinotecan in colorectal cancer Oncologist 6 2001 17 23
51. Y. Dai, S. Chen, L. Wang, X.Y. Pei, L.B. Kramer, P. Dent, and et al. Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF-κB and Bim Br J Haematol 153 2011 222 235
52. M.C. de Almagro, E. Selga, R. Thibaut, C. Porte, V. Noé, and C.J. Ciudad UDP-glucuronosyltransferase 1A6 overexpression in breast cancer cells resistant to methotrexate Biochem Pharmacol 8 2011 60 70
53. F.A. de Jong, M.J. de Jonge, J. Verweij, and R.H. Mathijssen Role of pharmacogenetics in irinotecan therapy Cancer Lett 234 2006 90 106
54. H. de Jonge, and D.R. Kuypers Pharmacogenetics in solid organ transplantation: current status and future directions Transplant Rev (Orlando) 22 2008 6 20
55. D.R. de Waart, M.L. Vlaming, C. Kunne, A.H. Schinkel, and R.P. Oude Elferink Complex pharmacokinetic behavior of ezetimibe depends on abcc2, abcc3, and abcg2 Drug Metab Dispos 37 2009 1698 1702
56. R.G. Deeley, C. Westlake, and S.P. Cole Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins Physiol Rev 86 2006 849 899
57. R.W. Dellinger, H.H. Matundan, A.S. Ahmed, P.H. Duong, and F.L. Meyskens Jr. Anti-cancer drugs elicit re-expression of UDP-glucuronosyltransferases in melanoma cells PLoS One 7 2012 e47696
58. J.M. Delou, A.G. Lopes, and M.A. Capella Unveiling the role of multidrug resistance proteins in hypertension Hypertension 54 2009 210 216
59. S.M. Dombrowski, S.Y. Desai, M. Marroni, L. Cucullo, K. Goodrich, W. Bingaman, and et al. Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy Epilepsia 42 2001 1501 1506
60. R. Eastell Treatment of postmenopausal osteoporosis N Engl J Med 338 1998 736 746
61. T. Efferth, and M. Volm Pharmacogenetics for individualized cancer chemotherapy Pharmacol Ther 107 2005 155 176
62. C. Fahrmayr, J. König, D. Auge, M. Mieth, and M.F. Fromm Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells Br J Pharmacol 165 2012 1836 1847
63. B. Fedejko-Kap, S.M. Bratton, M. Finel, A. Radominska-Pandya, and Z. Mazerska Role of human UDP-glucuronosyltransferases in the biotransformation of the triazoloacridinone and imidazoacridinone antitumor agents C-1305 and C-1311: highly selective substrates for UGT1A10 Drug Metab Dispos 40 2012 1736 1743
64. H.S. Feigelson, and B.E. Henderson Estrogens and breast cancer Carcinogenesis 17 1996 2279 2284
65. C. Felipe, T.V. de Sandes, E.L. Sampaio, S.I. Park, H.T. Silva Jr., and J.O. Medina Pestana Clinical impact of polymorphisms of transport proteins and enzymes involved in the metabolism of immunosuppressive drugs Transplant Proc 41 2009 1441 1455
66. J.I. Fletcher, M. Haber, M.J. Henderson, and M.D. Norris ABC transporters in cancer: more than just drug efflux pumps Nat Rev Cancer 10 2010 147 156
67. T.J. Franklin, V. Jacobs, G. Jones, P. Plé, and P. Bruneau Glucuronidation associated with intrinsic resistance to mycophenolic acid in human colorectal carcinoma cells Cancer Res 56 1996 984 987
68. H. Fujino, I. Hamada, S. Shimada, M. Yoneda, and J. Kojami Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: human UDP-glucuronosyltransferase enzymes involved in lactonization Xenobiotica 33 2003 27 41
69. J.F. Gagné, V. Montminy, P. Belanger, K. Journault, G. Gaucher, and C. Guillemette Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) Mol Pharmacol 62 2002 608 617
70. D.A. Gardner-Stephen, and P.I. Mackenzie Hepatocyte nuclear factor1 transcription factors are essential for the UDP-glucuronosyltransferase 1A9 promoter response to hepatocyte nuclear factor 4alpha Pharmacogenet Genomics 17 2007 25 36
71. F. Geng, Z. Jiao, Y.J. Dao, X.Y. Qiu, J.J. Ding, X.J. Shi, and et al. The association of the UGT1A8, SLCO1B3 and ABCC2/ABCG2 genetic polymorphisms with the pharmacokinetics of mycophenolic acid and its phenolic glucuronide metabolite in Chinese individuals Clin Chim Acta 413 2012 683 690
72. S.A. Gestl, M.D. Green, D.A. Shearer, E. Frauenhoffer, T.R. Tephly, and J. Weisz Expression of UGT2B7, a UDP-glucuronosyltransferase implicated in the metabolism of 4-hydroxyestrone and all-trans retinoic acid, in normal human breast parenchyma and in invasive and in situ breast cancers Am J Pathol 160 2002 1467 1479
73. A. Ghosal, N. Hapangama, Y. Yuan, J. Achanfuo-Yeboah, R. Iannucci, S. Chowdhury, and et al. Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of ezetimibe (Zetia) Drug Metab Dispos 32 2004 314 320
74. C. Ghosh, M. Hossain, V. Puvenna, J. Martinez-Gonzalez, A. Alexopolous, D. Janigro, and et al. Expression and functional relevance of UGT1A4 in a cohort of human drug-resistant epileptic brains Epilepsia 54 2013 1562 1570
75. R. Ghotbi, B. Mannheimer, E. Aklillu, A. Suda, L. Bertilsson, E. Eliasson, and et al. Carriers of the UGT1A4 142T>G gene variant are predisposed to reduced olanzapine exposure - an impact similar to male gender or smoking in schizophrenic patients Eur J Clin Pharmacol 66 2010 465 674
76. L. Giuliani, M. Ciotti, A. Stoppacciaro, A. Pasquini, I. Silvestri, A. de Matteis, and et al. UDP-glucuronosyltransferases 1A expression in human urinary bladder and colon cancer by immunohistochemistry Oncol Rep 13 2005 185 191
77. M.M. Gottesman, T. Fojo, and S.E. Bates Multidrug resistance in cancer: role of ATP-dependent transporters Nat Rev Cancer 2 2002 48 58
78. P.A. Gregory, D.A. Gardner-Stephen, R.H. Lewinsky, K.N. Duncliffe, and P.I. Mackenzie Cloning and characterization of the human UDP-glucuronosyltransferase 1A8, 1A9, and 1A10 gene promoters: differential regulation through an iterior-like region J Biol Chem 278 2003 36107 36114
79. P.A. Gregory, D.A. Gardner-Stephen, A. Rogers, M.Z. Michael, and P.I. Mackenzie The caudal-related homeodomain protein Cdx2 and hepatocyte nuclear factor 1alpha cooperatively regulate the UDP-glucuronosyltransferase 2B7 gene promoter Pharmacogenet Genomics 16 2006 527 536
80. P.A. Gregory, R.H. Lewinsky, D.A. Gardner-Stephen, and P.I. Mackenzie Coordinate regulation of the human UDP-glucuronosyltransferase 1A8, 1A9, and 1A10 genes by hepatocyte nuclear factor 1alpha and the caudal-related homeodomain protein 2 Mol Pharmacol 65 2004 953 963
81. C. Guillemette, E. Lévesque, M. Harvey, J. Bellemare, and V. Menard UGT genomic diversity: beyond gene duplication Drug Metab Rev 42 2010 22 42
82. A. Guo, W. Marinaro, P. Hu, and P.J. Sinko Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT) Drug Metab Dispos 30 2002 457 463
83. A. Habtewold, W. Amogne, E. Makonnen, G. Yimer, K.D. Riedel, N. Ueda, and et al. Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients J Antimicrob Chemother 66 2011 2350 2361
84. K. Hande, L. Anthony, R. Hamilton, R. Bennett, B. Sweetman, and R. Branch Identification of etoposide glucuronide as a major metabolite of etoposide in the rat and rabbit Cancer Res 48 1988 1829 1834
85. K.R. Hande, P.J. Wedlund, R.M. Noone, G.R. Wilkinson, F.A. Greco, and S.N. Wolff Pharmacokinetics of high-dose etoposide (VP-16-213) administrated to cancer patients Cancer Res 44 1984 379 382
86. N. Hanioka, H. Iwabu, H. Hanafusa, S. Nakada, and S. Narimatsu Expression and inducibility of UDP-glucuronosyltransferase 1As in MCF-7 human breast carcinoma cells Basic Clin Pharmacol Toxicol 110 2012 253 258
87. N. Hanioka, S. Ozawa, H. Jinno, M. Ando, Y. Saito, and J. Sawada Human liver UDP-glucuronosyltransferase isoforms involved in the glucuronidation of 7-ethyl-10-hydroxycamptothecin Xenobiotica 31 2001 687 699
88. N.M. Harris, W.R. Anderson, B.A. Lwaleed, A.J. Cooper, B.R. Birch, and L.Z. Solomon Epirubicin and meglumine gamma-linolenic acid: a logical choice of combination therapy for patients with superficial bladder carcinoma Cancer 97 2003 71 78
89. M. Hasegawa, H. Kusuhara, M. Adach, J.D. Schuetz, K. Takeuchi, Y. Sugiyama, and et al. Multidrug resistance-associated protein 4 is involved in the urinary excretion of hydrochlorothiazide and furosemide J Am Soc Nephrol 18 2007 37 45
90. M.H. Hazelhoff, M.S. Trebucobich, T.R. Stoyanoff, A.A. Chevalier, and A.M. Torres Amelioration of mercury nephrotoxicity after pharmacological manipulation of organic anion transporter 1 (Oat1) and multidrug resistance-associated protein 2 (Mrp2) with furosemide Toxicol Res 4 2015 1324 1332
91. T. Hirohashi, H. Suzuki, and Y. Sugiyama Characterization of the transport properties of cloned rat multidrug resistance-associated protein 3 (MRP3) J Biol Chem 274 1999 15181 15185
92. E. Hoffart, L. Ghebreghiorghis, A.K. Nussler, W.E. Thasler, T.S. Weiss, M. Schwab, and et al. Effects of atorvastatin metabolites on induction of drug-metabolizing enzymes and membrane transporters through human pregnane X receptor Br J Pharmacol 165 2012 1595 1608
93. G. Housman, S. Byler, S. Heerboth, K. Lapinska, M. Longacre, N. Snyder, and et al. Drug resistance in cancer: an overview Cancers 6 2014 1769 1792
94. Y.H. Hsiang, L.F. Liu, M.E. Wall, M.C. Wani, A.W. Nicholas, and G. Manikumar DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues Cancer Res 49 1989 4385 4389
95. D.G. Hu, and P.I. Mackenzie Estrogen receptor alpha, fos-related antigen-2, and c-Jun coordinately regulate human UDP glucuronosyltransferase 2B15 and 2B17 expression in response to 17beta-estradiol in MCF-7 cells Mol Pharmacol 76 2009 425 439
96. D.G. Hu, and P.I. Mackenzie Forkhead box protein A1 regulates UDP glucuronosyltransferase 2B15 gene transcription in LNCaP prostate cancer cells Drug Metab Dispos 38 2010 2105 2109
97. D.G. Hu, A. Rogers, and P.I. Mackenzie Epirubicin upregulates UDP glucuronosyltransferase 2B7 expression in liver cancer cells via the p53 pathway Mol Pharmacol 85 2014 887 897
98. I. Ieiri, C. Nishimura, K. Maeda, T. Sasaki, M. Kimura, T. Chiyoda, and et al. Pharmacokinetic and pharmacogenomic profiles of telmisartan after the oral microdose and therapeutic dose Pharmacogenet Genomics 21 2011 495 505
99. F. Innocenti, L. Iyer, J. Ramírez, M.D. Green, and M.J. Ratain Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7 Drug Metab Dispos 29 2001 686 692
100. F. Innocenti, E.E. Vokes, and M.J. Ratain Irinogenetics: what is the right star? J Clin Oncol 24 2006 2221 2224
101. N. Isambert, M. Campone, E. Bourbouloux, M. Drouin, A. Major, W. Yin, and et al. Evaluation of the safety of C-1311 (SYMADEX) administered in a phase 1 dose escalation trial as a weekly infusion for 3 consecutive weeks in patients with advanced solid tumours Eur J Cancer 46 2010 729 734
102. Y. Ishii, N. Iida, Y. Miyauchi, P.I. Mackenzie, and H. Yamada Inhibition of morphine glucuronidation in the liver microsomes of rats and humans by monoterpenoid alcohols Biol Pharm Bull 35 2012 1811 1817
103. L. Iyer, S. Das, L. Janisch, M. Wen, J. Ramírez, T. Karrison, and et al. UGT1A1∗28 polymorphism as a determinant of irinotecan disposition and toxicity Pharmacogenomics J 2 2002 43 47
104. L. Iyer, C.D. King, P.F. Whitington, M.D. Green, S.K. Roy, T.R. Tephly, and et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes J Clin Invest 101 1998 847 854
105. O. Janneh, E. Jones, B. Chandler, A. Owen, and S.H. Khoo Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes J Antimicrob Chemother 60 2007 987 993
106. G. Jedlitschky, I. Leier, U. Buchholz, K. Barnouin, G. Kurz, and D. Keppler Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump Cancer Res 56 1996 988 994
107. E.S. Jeong, Y.W. Kim, H.J. Kim, H.J. Shin, J.G. Shin, K.H. Kim, and et al. Glucuronidation of fimasartan, a new angiotensin receptor antagonist, is mainly mediated by UGT1A3 Xenobiotica 45 2015 10 18
108. P.M. Jones, and A.M. George The ABC transporter structure and mechanism: perspectives on recent research Cell Mol Life Sci 61 2004 682 699
109. V.C. Jordan "Studies on the estrogen receptor in breast cancer" - 20 years as a target for the treatment and prevention of cancer Breast Cancer Res Treat 36 1995 267 285
110. N. Jovanović, N. Božina, M. Lovrić, V. Medved, M. Jakovljević, and A.M. Peleš The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naïve patients with first-episode schizophrenia treated with risperidone Eur J Clin Pharmacol 66 2010 1109 1117
111. H. Joyce, A. McCann, M. Clynes, and A. Larkin Influence of multidrug resistance and drug transport proteins on chemotherapy drug metabolism Expert Opin Drug Metab Toxicol 11 2015 795 809
112. N. Kamiyama, S. Takagi, C. Yamamoto, T. Kudo, T. Nakagawa, M. Takahashi, and et al. Expression of ABC transporters in human hepatocyte carcinoma cells with cross-resistance to epirubicin and mitoxantrone Anticancer Res 26 2006 885 888
113. S.P. Kang, J. Ramirez, L. House, W. Zhang, S. Mirkov, W. Liu, and et al. A pharmacogenetic study of vorinostat glucuronidation Pharmacogenet Genomics 20 2010 638 641
114. N. Kartner, J.R. Riordan, and V. Ling Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines Science 221 1983 1285 1288
115. B.S. Katzenellenbogen, M.J. Norman, R.L. Eckert, S.W. Peltz, and W.F. Mangel Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxy-tamoxifen isomers in MCF-7 human breast cancer cells Cancer Res 44 1984 112 119
116. D.F.S. Kehrer, W. Yamamoto, J. Verweij, M.J.A. de Jonge, P. de Bruijn, and A. Sparreboom Factors involved in prolongation of the terminal disposition phase of SN-38: clinical and experimental studies Clin Cancer Res 6 2000 3451 3458
117. D.C. Kemp, P.W. Fan, and J.C. Stevens Characterization of raloxifene glucuronidation in vitro: contribution of intestinal metabolism to presystemic clearance Drug Metab Dispos 30 2002 694 700
118. D. Keppler, I. Leier, and G. Jedlitschky Transport of glutathione conjugates and glucuronides by the multidrug resistance proteins MRP1 and MRP2 Biol Chem 378 2000 787 791
119. O. Kerdpin, K.M. Knights, D.J. Elliot, and J.O. Miners In vitro characterisation of human renal and hepatic frusemide glucuronidation and identification of the UDP-glucuronosyltransferase enzymes involved in this pathway Biochem Pharmacol 76 2008 249 257
120. R.B. Kim, M.F. Fromm, C. Wandel, B. Leake, A.J. Wood, D.M. Roden, and et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors J Clin Invest 101 1998 289 294
121. K.M. Knights, and J.O. Miners Renal UDP-glucuronosyltransferases and the glucuronidation of xenobiotics and endogenous mediators Drug Metab Rev 42 2010 63 73
122. R.H. Knopp Drug treatment of lipid disorders N Engl J Med 341 1999 498 511
123. K. Kokawa, N. Kishi, H. Jinno, T. Tanaka-Kagawa, S. Narimatsu, and N. Hanioka Effect of UDP-glucuronosyltransferase 1A8 polymorphism on raloxifene glucuronidation Eur J Pharm Sci 49 2013 199 205
124. J. König, Y. Cui, A.T. Nies, and D. Keppler Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide J Biol Chem 275 2000 23161 23168
125. M.T. Kou Redox regulation of multidrug resistance in cancer chemotherapy: molecular mechanisms and therapeutic opportunities Antioxid Redox Signal 11 2009 99 133
126. H. Kubota, H. Ishihara, T. Langmann, G. Schmitz, B. Stieger, H.G. Wieser, and et al. Distribution and functional activity of P-glycoprotein and multidrug resistance-associated proteins in human brain microvascular endothelial cells in hippocampal sclerosis Epilepsy Res 68 2006 213 228
127. Y. Kutsuno, K. Sumida, T. Itoh, R.H. Tukey, and R. Fujiwara Glucuronidation of drugs in humanized UDP-glucuronosyltransferase 1 mice: similarity with glucuronidation in human liver microsomes Pharmacol Res Perspect 1 2013 e00002
128. A. Kwara, M. Lartey, I. Boamah, N.L. Rezk, J. Oliver-Commey, E. Kenu, and et al. Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7∗1c is associated with faster zidovudine clearance and glucuronidation J Clin Pharmacol 49 2009 1079 1090
129. A. Kwara, M. Lartey, K.W. Sagoe, E. Kenu, and M.H. Court CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients AIDS 23 2009 2101 2106
130. R. Lacchini, V.N. Figueiredo, C. Demach, F.B. Coeli-Lacchini, L.C. Martins, J. Yugar-Toledo, and et al. MDR-1 C3435T polymorphism may affect blood pressure in resistant hypertensive patients independently of its effects on aldosterone release J Renin Angiotensin Aldosterone Syst 15 2014 170 176
131. S. Lam, N. Partovi, L.S. Ting, and M.H. Ensom Corticosteroid interactions with cyclosporine, tacrolimus, mycophenolate, and sirolimus: fact or fiction? Ann Pharmacother 42 2008 1037 1047
132. C.J. Langer The global role of irinotecan in the treatment of lung cancer: 2003 update Oncology (Williston Park) 17 2003 30 40
133. D. Langford, A. Grigorian, R. Hurford, A. Adame, R.J. Ellis, L. Hansen, and et al. Altered P-glycoprotein expression in AIDS patients with HIV encephalitis J Neuropathol Exp Neurol 63 2004 1038 1047
134. A. Lazarowski, M. Massaro, A. Schteinschnaider, S. Intruvini, G. Sevlever, and A. Rabinowicz Neuronal MDR-1 gene expression and persistent low levels of anticonvulsants in a child with refractory epilepsy Ther Drug Monit 26 2004 44 46
135. E.M. Leslie, R.G. Deeley, and S.P.C. Cole Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense Toxicol Appl Pharmacol 204 2005 216 237
136. J. Li, M. Shi, Y. Cao, W. Yuan, T. Pang, B. Li, and et al. Knockdown of hypoxia-inducible factor-1alpha in breast carcinoma MCF-7 cells results in reduced tumor growth and increased sensitivity to methotrexate Biochem Biophys Res Commun 342 2006 1341 1351
137. E.A. Lien, E. Solheim, O.A. Lea, S. Lundgren, S. Kvinnsland, and P.M. Ueland Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment Cancer Res 49 1989 2175 2183
138. Y.C. Lim, Z. Desta, D.A. Flockhart, and T.C. Skaar Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen Cancer Chemother Pharmacol 55 2005 471 478
139. T.H. Lippert, H.J. Ruoff, and M. Volm Intrinsic and acquired drug resistance in malignant tumors. The main reason for therapeutic failure Arzneimittelforschung 58 2008 261 264
140. W. Liu, Q. Feng, Y. Li, Y. Ling, M. Hu, and Z. Liu Coupling of UDP-glucuronosyltransferases and multidrug resistance-associated proteins is responsible for the intestinal disposition and poor bioavailability of emodin Toxicol Appl Pharmacol 265 2012 316 324
141. W. Liu, Z. Zheng, X. Liu, S. Gao, L. Ye, Z. Yang, and et al. Sensitive and robust UPLC-MS/MS method to determine the gender-dependent pharmacokinetics in rats of emodin and its glucuronide J Pharm Biomed Anal 54 2011 1157 1162
142. K.P. Locher Structure and mechanism of ATP-binding cassette transporters Philos Trans R Soc B 364 2009 239 245
143. W. Löscher, and H. Potschka Blood-brain barrier active efflux Transporters: ATP-binding cassette gene family NeuroRx 2 2005 86 98
144. W. Löscher, and H. Potschka Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases Prog Neurobiol 76 2005 22 76
145. W. Löscher, and H. Potschka Drug resistance in brain diseases and the role of drug efflux transporters Nat Rev Neurosci 6 2005 591 602
146. S.V. Löser, J. Meyer, S. Freudenthaler, M. Sattler, C. Desel, I. Meineke, and et al. Morphine-6-O-beta-d-glucuronide but not morphine-3-O-beta-d-glucuronide binds to mu-, delta- and kappa- specific opioid binding sites in cerebral membranes Naunyn Schmiedebergs Arch Pharmacol 354 1996 192 197
147. M. Lovrić, N. Božina, S. Hajnšek, M.R. Kuzman, D. Sporiš, Z. Lalić, and et al. Association between lamotrigine concentrations and ABCB1 polymorphisms in patients with epilepsy Ther Drug Monit 34 2012 518 525
148. L. Lu, J. Zhou, J. Shi, X.J. Peng, X.X. Qi, Y. Wang, and et al. Drug-metabolizing activity, protein and gene expression of UDP-glucuronosyltransferases are significantly altered in hepatocellular carcinoma patients PLoS One 10 2015 e0127524
149. C. Luna-Tortós, M. Fedrowitz, and W. Löscher Evaluation of transport of common antiepileptic drugs by human multidrug resistance-associated proteins (MRP1, 2 and 5) that are overexpressed in pharmacoresistant epilepsy Neuropharmacology 58 2010 1019 1032
150. P.I. Mackenzie, K.W. Bock, B. Burchell, C. Guillemette, S. Ikushiro, T. Iyanagi, and et al. Nomenclature update for the mammalian UDP-glucuronosyltransferase (UGT) gene superfamily Pharmacogenet Genomics 15 2005 677 685
151. P.I. Mackenzie, A. Rogers, D.J. Elliot, N. Chau, J.A. Hulin, J.O. Miners, and et al. The novel UDP glucuronosyltransferase 3A2: cloning, catalytic properties, and tissue distribution Mol Pharmacol 79 2011 472 478
152. G. Margaillan, M. Rouleau, J.K. Fallon, P. Caron, L. Villeneuve, V. Turcotte, and et al. Quantitative profiling of human renal UDP-glucuronosyltransferases and glucuronidation activity: a comparison of normal and tumoral kidney tissues Drug Metab Dispos 43 2015 611 619
153. R.H. Mathijssen, R.J. van Alphen, J. Verweij, W.J. Loos, K. Nooter, G. Stoter, and et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11) Clin Cancer Res 8 2001 2182 2194
154. I. Meijerman, J.H. Beijnen, and J.H.M. Schellens Combined action and regulation of phase II enzymes and multidrug resistance proteins in multidrug resistance in cancer Cancer Treat Rev 34 2008 505 520
155. I.F. Metzger, T.C. Quigg, N. Epstein, A.O. Aregbe, N. Thong, J.T. Callaghan, and et al. Substantial effect of efavirenz monotherapy on bilirubin levels in healthy volunteers Curr Ther Res Clin Exp 76 2014 64 69
156. H.E. Meyer zu Schwabedissen, S. Oswald, C. Bresser, A. Nassif, C. Modess, Z. Desta, and et al. Compartment-specific gene regulation of the CAR inducer efavirenz in vivo Clin Pharmacol Ther 92 2012 103 111
157. V. Michaud, T. Bar-Magen, J. Turgeon, D. Flockhart, Z. Desta, and M.A. Wainberg The dual role of pharmacogenetics in HIV treatment: mutations and polymorphisms regulating antiretroviral drug resistance and disposition Pharmacol Rev 64 2012 803 833
158. M. Miura, S. Satoh, K. Inoue, M. Saito, T. Habuchi, and T. Suzuki Telmisartan pharmacokinetics in Japanese renal transplant recipients Clin Chim Acta 399 2009 83 87
159. A. Mori, Y. Maruo, M. Iwai, H. Sato, and Y. Takeuchi UDP-glucuronosyltransferase 1A4 polymorphisms in a Japanese population and kinetics of clozapine glucuronidation Drug Metab Dispos 33 2005 672 675
160. S. Nagar, and R.L. Blanchartd Pharmacogenetics of uridine diphosphoglucuronosyltransferase (UGT) 1A family members and its role in patient response to irinotecan Drug Metab Rev 38 2006 393 409
161. M. Niemira, J. Dastych, and Z. Mazerska Pregnane X receptor dependent up-regulation of CYP2C9 and CYP3A4 in tumor cells by antitumor acridine agents, C-1748 and C-1305, selectively diminished under hypoxia Biochem Pharmacol 86 2013 231 241
162. P.J. O'Dwyer, B. Leyland-Jones, M.T. Alonso, S. Marsoni, and R.E. Wittes Etoposide (VP-16-213): current status of an active anticancer drug N Engl J Med 312 1985 692 700
163. S. Oda, T. Fukami, T. Yokoi, and M. Nakajima Epigenetic regulation of tissue-specific expression of human UDP-glucuronosyltransferase (UGT) 1A10 Biochem Pharmacol 87 2014 660 667
164. S. Oda, T. Fukumi, T. Yokoi, and M. Nakajima A comprehensive review of UDP-glucuronosyltransferase and esterases for drug development Drug Metab Pharmacokinet 30 2015 30 51
165. K. Ogura, Y. Ishikawa, T. Kaku, T. Nishiyama, T. Ohnuma, K. Muro, and et al. Quaternary ammonium-linked glucuronidation of trans-4-hydroxytamoxifen, an active metabolite of tamoxifen, by human liver microsomes and UDP-glucuronosyltransferase 1A4 Biochem Pharmacol 71 2006 1358 1369
166. T. Oguri, T. Takahashi, M. Miyazaki, T. Isobe, N. Kohno, P.I. Mackenzie, and et al. UGT1A10 is responsible for SN-38 glucuronidation and its expression in human lung cancers Anticancer Res 24 2004 2893 2896
167. H. Ohdan Quantification of T-cell proliferation for individualizing immunosuppressive therapy for transplantation patients Clin Pharmacol Ther 87 2010 23 26
168. S. Ohno, and S. Nakajin Determination of mRNA expression of human UDP-glucuronosyltransferases and application for localization in various human tissues by real-time reverse transcriptase-polymerase chain reaction Drug Metab Dispos 37 2009 32 40
169. J.A. Olson, R.C. Moon, M.W. Anders, C. Fenselau, and B. Shane Enhancement of biological activity by conjugation reactions J Nutr 122 1992 615 624
170. D. Omrod, K. Holm, K. Goa, and C. Spencer Epirubicin: a review of its efficacy as adjuvant therapy and in the treatment of metastatic disease in breast cancer Drugs Aging 15 1999 389 416
171. S. Oswald, S. Westrup, M. Grube, H.K. Kroemer, W. Weitschies, and W. Siegmund Disposition and sterol-lowering effect of ezetimibe in multidrug resistance-associated protein 2-deficient rats J Pharmacol Exp Ther 318 2006 1293 1299
172. M. Ouzzine, S. Gulberti, N. Ramalanjaona, J. Magdalou, and S. Fournel-Gigleux The UDP-glucuronosyltransferases of the blood-brain barrier: their role in drug metabolism and detoxication Front Cell Neurosci 8 2014 349
173. S. Palacios, M. Brincat, C.T. Erel, M. Gambacciani, I. Lambrinoudaki, M.H. Moen, and et al. EMAS clinical guide: selective estrogen receptor modulators for postmenopausal osteoporosis Maturitas 71 2012 194 198
174. W.B. Park, P.G. Choe, K.H. Song, J.H. Jeon, S.W. Park, H.B. Kim, and et al. Genetic factors influencing severe atazanavir-associated hyperbilirubinemia in a population with low UDP-glucuronosyltransferase 1A1∗28 allele frequency Clin Infect Dis 51 2010 101 106
175. D. Paul, K.M. Standifer, C.E. Inturrisi, and G.W. Pasternak Pharmacological characterization of morphine-6 beta-glucuronide, a very potent morphine metabolite J Pharmacol Exp Ther 251 1989 477 483
176. M. Pawłowska, R. Chu, B. Fedejko-Kap, E. Augustin, Z. Mazerska, A. Radominska-Pandya, and et al. Metabolic transformation of antitumor acridinone C-1305 but not C-1311 via selective cellular expression of UGT1A10 increases cytotoxic response: implications for clinical use Drug Metab Dispos 41 2013 414 421
177. M.D. Perloff, L.L. von Moltke, J.M. Fahey, and D.J. Greenblatt Induction of P-glycoprotein expression and activity by ritonavir in bovine brain microvessel endothelial cells J Pharm Pharmacol 59 2007 947 953
178. N. Picard, D. Ratanasavanh, A. Prémaud, Y. Le Meur, and P. Marquet Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism Drug Metab Dispos 33 2005 139 146
179. H. Potschka, M. Fedrowitz, and W. Löscher Multidrug resistance protein MRP2 contributes to blood-brain barrier function and restricts antiepileptic drug activity J Pharmacol Exp Ther 306 2003 124 131
180. T. Prueksaritanont, R. Subramanian, X. Fang, B. Ma, Y. Qiu, J.H. Lin, and et al. Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization Drug Metab Dispos 30 2002 505 512
181. Y.G. Puranik, A.K. Birnbaum, S.E. Marino, G. Ahmed, J.C. Cloyd, R.P. Remmel, and et al. Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy Pharmacogenomics 14 2013 35 45
182. A. Radominska-Pandya, S.M. Bratton, M.R. Redinbo, and M.J. Miley The crystal structure of human UDP-glucuronosyltransferase 2B7 C-terminal end is the first mammalian UGT target to be revealed: the significance for human UGTs from both the 1A and 2B families Drug Metab Rev 42 2010 133 144
183. C. Raynal, J.M. Pascussi, G. Leguelinel, C. Breuker, J. Kantar, B. Lallemant, and et al. Pregnane X Receptor (PXR) expression in colorectal cancer cells restricts irinotecan chemosensitivity through enhanced SN-38 glucuronidation Mol Cancer 9 2010 46
184. M.J. Reese, P.M. Savina, G.T. Generaux, H. Tracey, J.E. Humphreys, E. Kanaoka, and et al. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor Drug Metab Dispos 41 2013 353 361
185. S. Riedmaier, K. Klein, U. Hofmann, J.E. Keskitalo, P.J. Neuvonen, M. Schwab, and et al. UDP-glucuronosyltransferase (UGT) polymorphisms affect atorvastatin lactonization in vitro and in vivo Clin Pharmacol Ther 87 2010 65 73
186. A. Ring, and M. Dowsett Mechanisms of tamoxifen resistance Endocr Relat Cancer 11 2004 643 658
187. P.T. Ronaldson, Y. Persidsky, and R. Bendayan Regulation of ABC membrane transporters in glial cells: relevance to the pharmacotherapy of brain HIV-1 infection Glia 56 2008 1711 1735
188. W. Ross, T. Rowe, B. Glisson, J. Yalowich, and L. Liu Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage Cancer Res 44 1984 5857 5860
189. E.A. Roundhill, J.I. Fletcher, M. Haber, and M.D. Norris Clinical relevance of multidrug-resistance-proteins (MRPs) for anticancer drug resistance and prognosis T. Efferth, Resistance to Targeted ABC Transporters in Cancer 2015 Springer International Publishing Switzerland 10.1007/978-3-319-09801-2-2
190. A. Rowland, J.O. Miners, and P.I. Mackenzie The UDP-glucuronosyltransferases: their role in drug metabolism and detoxification Int J Biochem Cell Biol 45 2013 1121 1132
191. B.C. Sallustio, L.A. Harkin, M.C. Mann, S.J. Krivickas, and P.C. Burcham Genotoxicity of acyl glucuronide metabolites formed from clofibric acid and gemfibrozil: a novel role for phase-II-mediated bioactivation in the hepatocarcinogenicity of the parent aglycones? Toxicol Appl Pharmacol 147 1997 459 464
192. T. Satoh, T. Ura, Y. Yamada, K. Yamazaki, T. Tsujinaka, M. Munakata, and et al. Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1∗28 and/or UGT1A1∗6 polymorphisms Cancer Sci 102 2011 1868 1873
193. A.H. Schinkel, and J.W. Jonker Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview Adv Drug Deliv Rev 55 2003 3 29
194. T.J. Schirris, T. Ritschel, A. Bilos, J.A. Smeitink, and F.G. Russel Statin lactonization by uridine 5′-diphospho-glucuronosyltransferases (UGTs) Mol Pharm 12 2015 4048 4055
195. D. Schmidt, and W. Löscher Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms Epilepsia 46 2005 858 877
196. L. Schmitt, and R. Tampé Structure and mechanism of ABC transporters Curr Opin Struct Biol 1 2002 754 760
197. D. Sehrt, S. Vormfelde, M. Toliat, P. Nürnberg, M. Schirmer, and J. Brockmoller Genetic polymorphisms in the glucuronosyltransferases 1A1, 1A8 and 1A9 in relation to pharmacokinetics of furosemide Clin Pharmacol Ther 77 2005 P34
198. T. Shiraga, Z. Tozuka, R. Ishimura, A. Kawamura, and A. Kagayama Identification of cytochrome P450 enzymes involved in the metabolism of FK228, a potent histone deacetylase inhibitor, in human liver microsomes Biol Pharm Bull 28 2005 124 129
199. S. Shukla, R.W. Robey, S.E. Bates, and S.V. Ambudkar The calcium channel blockers, 1,4-dihydropyridines, are substrates of the multidrug resistance-linked ABC drug transporter, ABCG2 Biochemistry 45 2006 8940 8951
200. G. Siest, E. Jeannesson, and S. Visvikis-Siest Enzymes and pharmacogenetics of cardiovascular drugs Clin Chim Acta 381 2007 26 31
201. N. Singkham, S. Towanabut, S. Lertkachatarn, and B. Punyawudho Influence of the UGT2B7 -161C>T polymorphism on the population pharmacokinetics of lamotrigine in Thai patients Eur J Clin Pharmacol 69 2013 1285 1291
202. S.M. Sisodiya, W.R. Lin, B.N. Harding, M.V. Squier, and M. Thom Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy Brain 125 2002 22 31
203. H.F. Stahelin, and A. von Wartburg The chemical and biological route from podophyllotoxin glucoside to etoposide: ninth Cain memorial Award lecture Cancer Res 51 1991 5 15
204. A.G. Staines, M.W. Coughtrie, and B. Burchell N-glucuronidation of carbamazepine in human tissues is mediated by UGT2B7 J Pharmacol Exp Ther 311 2004 1131 1137
205. A. Starlard-Davenport, B. Lyn-Cook, F.A. Beland, and I.P. Pogribny The role of UDP-glucuronosyltransferases and drug transporters in breast cancer drug resistance Exp Oncol 32 2010 172 180
206. A. Starlard-Davenport, B. Lyn-Cook, and A. Radominska-Pandya Novel identification of UDP-glucuronosyltransferase 1A10 as an estrogen-regulated target gene Steroids 73 2008 139 147
207. A. Starlard-Davenport, B. Lyn-Cook, and A. Radominska-Pandya Identification of UDP-glucuronosyltransferase 1A10 in non-malignant and malignant human breast tissues Steroids 73 2008 611 620
208. A. Starlard-Davenport, Y. Xiong, S. Bratton, A. Gallus-Zawada, M. Finel, and A. Radominska-Pandya Phenylalanine90 and phenylalanine93 are crucial amino acids within the estrogen binding site of the human UDP-glucuronosyltransferase 1A10 Steroids 72 2007 85 94
209. F. Staud, and P. Pavek Breast cancer resistance protein (BCRP/ABCG2) Int J Biochem Cell Biol 37 2005 720 725
210. N.L. Steele, J.A. Plumb, L. Vidal, J. Tjornelund, P. Knoblauch, A. Rasmussen, and et al. A phase I pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors Clin Cancer Res 14 2008 804 810
211. A.N. Stone, P.I. Mackenzie, A. Galetin, J.B. Houston, and J.O. Miners Isoform selectivity and kinetics of morphine 3- and 6-glucuronidation by human UDP-glucuronosyltransferases: evidence for atypical glucuronidation kinetics by UGT2B7 Drug Metab Dispos 31 2003 1086 1089
212. C.P. Strassburg, N. Nguyen, M.P. Manns, and R.H. Tukey UDP-glucuronosyltransferase activity in human liver and colon Gastroenterology 116 1999 149 160
213. Y. Sugiyama, Y. Kato, and X. Chu Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: role of canalicular multispecific organic anion transporter and P-glycoprotein Cancer Chemother Pharmacol 42 1998 S44 S49 (Suppl.)
214. D. Sun, G. Chen, R.W. Dellinger, K. Duncan, J.L. Fang, and P. Lazarus Characterization of tamoxifen and 4-hydroxytamoxifen glucuronidation by human UGT1A4 variants Breast Cancer Res 8 2006 R50
215. D. Sun, A.K. Sharma, R.W. Dellinger, A.S. Blevis-Primeau, R.M. Balliet, G. Chen, and et al. Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases Drug Metab Dispos 35 2007 2006 2014
216. G. Szakács, J.K. Paterson, J.A. Ludwig, C. Booth-Genthe, and M.M. Gottesman Targeting multidrug resistance in cancer Nat Rev Drug Discov 5 2006 219 234
217. C.E. Szoeke, M. Newton, J.M. Wood, D. Goldstein, S.F. Berkovic, T.J. OBrien, and et al. Update on pharmacogenetics in epilepsy: a brief review Lancet Neurol 5 2006 189 196
218. A.H. Tolson, and H. Wang Regulation of drug-metabolizing enzymes by xenobiotic receptors: PXR and CAR Adv Drug Deliv Rev 62 2010 1238 1249
219. C. Toussaint, N. Albin, L. Massaad, D. Grunenwald, O. Parise Jr., J. Morizet, and et al. Main drug- and carcinogen-metabolizing enzyme systems in human non-small cell lung cancer and peritumoral tissues Cancer Res 53 1993 4608 4612
220. T. Trdan Lušin, A. Mohar, B. Stieber, G.A. Kullak-Ublick, J. Marc, B. Ostanek, and et al. Influence of hepatic and intestinal efflux transporters and their genetic variants on the pharmacokinetics and pharmacodynamics of raloxifene in osteoporosis treatment Transl Res 160 2012 298 308
221. J. Trontelj, J. Marc, A. Zavratnik, M. Bogataj, and A. Mohar Effects of UGT1A1∗28 polymorphism on raloxifene pharmacokinetics and pharmacodynamics Br J Clin Pharmacol 67 2009 437 444
222. R.H. Tukey, and C.P. Strassburg Human UDP-glucuronosyltransferases: metabolism, expression and disease Annu Rev Pharmacol Toxicol 40 2000 581 616
223. M. Uhr, M.T. Grauer, and F. Holsboer Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption Biol Psychiatry 54 2003 840 846
224. M. Uhr, M.T. Grauer, A. Yassouridis, and M. Ebinger Blood-brain barrier penetration and pharmacokinetics of amitriptyline and its metabolites in p-glycoprotein (abcb1ab) knock-out mice and controls J Psychiatr Res 41 2007 179 188
225. M. Uhr, A. Tontsch, C. Namendorf, S. Ripke, S. Lucae, M. Ising, and et al. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression Neuron 57 2008 203 209
226. S. Vaidyanathan, G. Camenisch, H. Schuetz, C. Reynolds, C.M. Yeh, M.N. Bizot, and et al. Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren J Clin Pharmacol 48 2008 1323 1338
227. D.M. Vigushin, and R.C. Coombes Histone deacetylase inhibitors in cancer treatment Anticancer Drugs 13 2002 1 13
228. D. Vishnuvardhan, L.L. Moltke, C. Richert, and D.J. Greenblatt Lopinavir: acute exposure inhibits P-glycoprotein; extended exposure induces P-glycoprotein AIDS 17 2003 1092 1094
229. E.L. Volk, and E. Schneider Wild-type breast cancer resistance protein (BCRP/ABCG2) is a Methotrexate Polyglutamate Transporter1 Cancer Res 63 2003 5538 5543
230. S. Wang, D.P. Hartley, S.L. Ciccotto, S.H. Vincent, R.B. Franklin, and M.S. Kim Induction of hepatic phase II drug-metabolizing enzymes by 1,7-phenanthroline in rats is accompanied by induction of MRP3 Drug Metab Dispos 31 2003 773 775
231. L.Z. Wang, J. Ramirez, W. Yeo, M.Y. Chan, W.L. Thuya, J.Y. Lau, and et al. Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patients PLoS One 8 2013 e54522
232. Y. Watanabe, M. Nakajima, N. Ohashi, T. Kume, and T. Yokoi Glucuronidation of etoposide in human liver microsomes is specifically catalyzed by UDP-glucuronosyltransferase 1A1 Drug Metab Dispos 31 2003 589 595
233. H. Weenen, J. Lankelma, P.G. Penders, J.G. McVie, W.W. ten Bokkel Huinink, M.M. de Planque, and et al. Pharmacokinetics of 4′-epi-doxorubicin in man Invest New Drugs 1 1983 59 64
234. H. Weenen, J.M. van Maanen, M.M. de Planque, J.G. McVie, and H.M. Pinedo Metabolism of 4′-modified analogs of doxorubicin. Unique glucuronidation pathway for 4′-epidoxorubicin Eur J Cancer Clin Oncol 20 1984 919 926
235. J. Weiss, A. Sauer, N. Divac, M. Herzog, E. Schwedhelm, R.H. Böger, and et al. Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters Biopharm Drug Dispos 31 2010 150 161
236. Z. Wen, M.N. Tallman, S.Y. Ali, and P.C. Smith UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics Drug Metab Dispos 35 2007 371 380
237. L.A. Wenning, A.S. Petry, J.T. Kost, B. Jin, S.A. Breidinger, I. DeLepeleire, and et al. Pharmacokinetics of raltegravir in individuals with UGT1A1 polymorphisms Clin Pharmacol Ther 85 2009 623 627
238. I.N. White Tamoxifen: is it safe? Comparison of activation and detoxication mechanisms in rodents and humans Curr Drug Metab 4 2003 223 239
239. P.R. Wielinga, H.V. Westerhoff, and J. Lankelma The relative importance of passive and P-glycoprotein mediatedanthracycline efflux from multidrug-resistant cells Eur J Biochem 267 2000 649 657
240. Q. Xiang, F. Yu, J. LV, X. Zhao, J. Han, Y. Zhou, and et al. Integration of genetic and clinical data to analyze pharmacokinetic profile of mycophenolic acid in a population of Chinese patients with glomerular disease Int Res J Pharm Pharmacol 3 2013 19 28
241. D. Xu, T. Nishimura, S. Nishimura, H. Zhang, M. Zheng, Y.Y. Guo, and et al. Fialuridine induces acute liver failure in chimeric TK-NOG mice: a model for detecting hepatic drug toxicity prior to human testing PLoS Med 11 2014 e1001628
242. A. Yamada, K. Maeda, N. Ishiguro, Y. Tsuda, T. Igarashi, T. Ebner, and et al. The impact of pharmacogenetics of metabolic enzymes and transporters on the pharmacokinetics of telmisartan in healthy volunteers Pharmacogenet Genomics 21 2011 523 530
243. H. Yamanaka, M. Nakajima, Y. Hara, M. Katoh, O. Tachibana, J. Yamashita, and et al. Urinary excretion of phenytoin metabolites, 5-(4′-hydroxyphenyl)-5-phenylhydantoin and its O-glucuronide in humans and analysis of genetic polymorphisms of UDP-glucuronosyltransferases Drug Metab Pharmacokinet 20 2005 135 143
244. N. Yasui-Furukori, M. Saito, T. Nakagami, A. Kanada, T. Tateishi, and S. Kaneko Association between multidrug resistance 1 (MDR1) gene polymorphisms and therapeutic response to bromperidol in schizophrenic patients: a preliminary study Prog Neuropsychopharmacol Biol Psychiatry 30 2006 286 291
245. L. Yilmaz, E. Borazan, T. Aytekin, I. Baskonus, A. Aytekin, S. Oztuzcu, and et al. Increased UGT1A3 and UGT1A7 expression is associated with pancreatic cancer Asian Pac J Cancer Prev 16 2015 1651 1655
246. H.A. Zahreddine, and K.L. Borden Molecular pathways: GLI1-induced drug glucuronidation in resistant cancer cells Clin Cancer Res 21 2015 2207 2210
247. H.A. Zahreddine, B. Culjkovic-Kraljacic, S. Assouline, P. Gendron, A.A. Romeo, S.J. Morris, and et al. The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation Nature 511 2014 90 93
248. M.J. Zamek-Gliszczynski, K.A. Hoffmaster, K. Nezasa, M.N. Tallman, and K.L.R. Brouwer Integration of hepatic drug transporters and phase II metabolizing enzymes: mechanisms of hepatic excretion of sulfate, glucuronide, and glutathione metabolites Eur J Pharm Sci 27 2006 447 486
249. J.A. Zastre, G.N. Chan, P.T. Ronaldson, M. Ramaswamy, P.O. Couraud, I.A. Romero, and et al. Up-regulation of P-glycoprotein by HIV protease inhibitors in a human brain microvessel endothelial cell line J Neurosci Res 87 2009 1023 1036
250. M.J. Zaya, R.N. Hines, and J.C. Stevens Epirubicin glucuronidation and UGT2B7 developmental expression Drug Metab Dispos 34 2006 2097 2101
251. N. Zelcer, T. Saeki, G. Reid, J.H. Beijnen, and P. Borst Characterization of drug transport by the Human Multidrug Resistance Protein 3 (ABCC3) J Biol Chem 276 2001 46400 46407